Abstract 2973
Background
Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare entity representing ≤ 2% of extra-nodal non-Hodgkin lymphoma. We aimed to define clinical profile, prognostic factors and the incidence of the central nervous system (CNS) relapse in the era of rituximab and clarify the prognostic value of beta2 microglobulin(B2M), interlukins-6 (IL-6) and interlukin -10(IL-10).
Methods
Between Jan 2012 to Dec 2016, a prospective analysis of 28 patients presenting to 7 academic Egyptian centers. All patients were females. Only patients with newly diagnosed stage I and II disease DLBCL were included. Patients with evidence of baseline CNS disease and patients with hepatitis B and HIV were excluded. All patients were scheduled to receive R-CHOP protocol plus involved- field radiotherapy. The prognostic significance of B2M, and IL-6 and 10 were assessed.
Results
About 75% presented with breast mass, 4 cases with inflammatory symptoms, 3 cases were discovered by mammography. Right breast was more involved (64%), 86% had ≤ 1 ECOG performance status, and LDH elevated was in 39% and 18% had B symptoms. HCV was positive in 32% (9 patients). Stage I was detected in 57%. The stage–modified International prognostic index was ≤1 in 54%. Ten cases underwent breast surgery (2 modified radical mastectomy, 8 conservative breast surgery). Complete response was achieved in 23/28 (82%) with median follow-up of 28 months, 39% of patients had relapsed, contralateral breast was the site of initial relapse in two cases, 11% developed CNS relapse and 21% in other nodal and extranodal sites. Three years disease free survival and overall survival were 68% and 79%. Favorable prognostic factors according to univariate analysis were stage I, IPI≤1, tumor size < 5cm, B2M. IL6 and IL-10, while for multivariate analysis they were IPI≤1 and B2 M and IL-6.
Conclusions
Primary breast DLBCL has high rate of CNS relapse in spite of era of rituximab so CT or MRI of CNS is necessary during follow-up. Prophylaxis to CNS should be considered in the initial treatment to improve outcome. In addition, assessment of pretreatment serum levels of B2M, and IL-6 in newly diagnosed DLBCL may indicate a possible prognostic role.
Clinical trial identification
Legal entity responsible for the study
Lobna Ezz el-arab.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract